Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience

被引：16
|
作者：
Sandoval-Sus, Jose D. [1 ]
Chavez, Julio C. [2 ]
Dalia, Samir [3 ]
Bello, Celeste M. [4 ]
Shah, Bijal D. [2 ]
Ho, Viet Q. [2 ]
Nodzon, Lisa [4 ]
Kharfan-Dabaja, Mohamed A. [5 ]
Sotomayor, Eduardo M. [6 ]
Sokol, Lubomir [7 ]
Pinilla-Ibarz, Javier [4 ]
机构：
[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Malignant Hematol, Tampa, FL 33682 USA
[3] Mercy Clin Oncol & Hematol, Joplin, MO USA
[4] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA
[5] Univ S Florida, H Lee Moffitt Canc Ctr, Blood & Marrow Transplantat, Tampa, FL 33682 USA
[6] George Washington Univ, Ctr Canc, Div Hematol Oncol, Washington, DC USA
[7] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL 33612 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2945.2945
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib
    Machnicki, Marcin M.
    Gorniak, Patryk
    Pepek, Monika
    Szymczyk, Agnieszka
    Iskierka-Jazdzewska, Elzbieta
    Steckiewicz, Pawel
    Bluszcz, Aleksandra
    Rydzanicz, Malgorzata
    Hus, Marek
    Ploski, Rafal
    Makuch-Lasica, Hanna
    Nowak, Grazyna
    Juszczynski, Przemyslaw
    Jamroziak, Krzysztof
    Stoklosa, Tomasz
    Pula, Bartosz
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (03) : 320 - 326
  • [32] Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
    Rogers, Kerry
    Thompson, Philip
    Allan, John
    Coleman, Morton
    Sharman, Jeff
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 4 - 5
  • [33] Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Jones, Daniel
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Patel, Priti
    Wang, Min Hui
    Kipps, Thomas J.
    HAEMATOLOGICA, 2021, 106 (09) : 2364 - 2373
  • [34] Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
    O'Brien, Susan M.
    Byrd, John C.
    Hillmen, Peter
    Coutre, Steven
    Brown, Jennifer R.
    Barr, Paul M.
    Barrientos, Jacqueline C.
    Devereux, Stephen
    Robak, Tadeusz
    Reddy, Nishitha M.
    Kipps, Thomas J.
    Tedeschi, Alessandra
    Cynnbalista, Florence
    Ghia, Paolo
    Chang, Stephen
    Ninomoto, Joi
    James, Danelle F.
    Burger, Jan A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (05) : 554 - 562
  • [35] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 22 - 23
  • [36] Commentary on “real world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: a meta-analysis of clinical studies”
    Ali Beheshti Namdar
    Masoud Keikha
    BMC Pharmacology and Toxicology, 26 (1)
  • [37] COST-EFFECTIVENESS OF IBRUTINIB AND RITUXIMAB FOR THE RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN CHINA
    Yang, F.
    Kumar, A.
    Rojanasarot, S.
    Schommer, J. C.
    Shao, R.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [38] A DOSE ESCALATION STUDY OF IBRUTINIB WITH LENALIDOMIDE FOR RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
    Pollyea, D.
    Gore, L.
    Gutman, J.
    Eckhardt, S. G.
    Hagelstrom, N.
    Coutre, S.
    Thirman, M.
    Byrd, J.
    ANNALS OF ONCOLOGY, 2013, 24 : 33 - 33
  • [39] A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Pollyea, Daniel A.
    Coutre, Steven
    Gore, Lia
    Adler, Nichole
    Harris, Pamela
    Phelps, Mitch A.
    Johnson, Amy J.
    Ling, YongHua
    Li, Hao
    Gutman, Jonathan A.
    Byrd, John C.
    BLOOD, 2014, 124 (21)
  • [40] Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials
    Joffe, Erel
    Goldschmidt, Neta
    Bairey, Osnat
    Fineman, Riva
    Ruchlemer, Rosa
    Rahimi-Levene, Naomi
    Shvidel, Lev
    Greenbaum, Uri
    Aviv, Ariel
    Tadmor, Tamar
    Braester, Andrea
    Arad, Ariela
    Polliack, Aaron
    Herishanu, Yair
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (03) : 399 - 406
12345